Leaders to announce licensing of UT Health Science Center intellectual property to Rapamycin Holdings Inc.
December 5, 2012
etails concerning the licensing of rapamycin-related intellectual property developed at the UT Health Science Center San Antonio to an emerging spin-out company, Rapamycin Holdings Inc. Rapamycin, a drug federally approved to suppress organ rejection, continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases.
